Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D006063:Chorionic Gonadotropin / Q000097:blood*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D013724:Teratoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage; D000509:alpha-Fetoproteins / Q000032:analysis*
D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D001761:Bleomycin; D003609:Dactinomycin; D014747:Vinblastine; D003520:Cyclophosphamide